New gene therapies may soon treat dozens of rare diseases, but million-dollar price tags will put them out of reach for many
By Kevin Doxzen,
The Conversation
| 08. 31. 2021
Zolgensma – which treats spinal muscular atrophy, a rare genetic disease that damages nerve cells, leading to muscle decay – is currently the most expensive drug in the world. A one-time treatment of the life-saving drug for a young child costs US$2.1 million.
While Zolgensma’s exorbitant price is an outlier today, by the end of the decade there’ll be dozens of cell and gene therapies, costing hundreds of thousands to millions of dollars for a single dose. The Food and Drug Administration predicts that by 2025 it will be approving 10 to 20 cell and gene therapies every year.
I’m a biotechnology and policy expert focused on improving access to cell and gene therapies. While these forthcoming treatments have the potential to save many lives and ease much suffering, health care systems around the world aren’t equipped to handle them. Creative new payment systems will be necessary to ensure everyone has equal access to these therapies.
The rise of gene therapies
Currently, only 5% of the roughly 7,000 rare diseases have an FDA-approved drug, leaving thousands of conditions... see more
Related Articles
By Lisa C. Ikemoto, Los Angeles Times | 07.07.2022
A few days after the Supreme Court overturned Roe vs. Wade, Boston IVF, a fertility company with centers in six states, posted a statement that speaks to the havoc this decision will wreak not just for abortions, but for...
Several new opinion polls on human biotechnology issues have recently come to our attention and two of them are discussed here. As is all too typical of polling on these complex matters, it is not clear that respondents were aware of, or informed about, key background information that would shield them from drawing false conclusions, as discussed below. (For summaries of these and older opinion polls on topics related to heritable human genome editing and cloning or genetically modifying animals...
By Antonio Regalado, MIT Technology Review | 07.12.2022
A volunteer in New Zealand has become the first person to undergo DNA editing in order to lower their blood cholesterol, a step that may foreshadow wide use of the technology to prevent heart attacks.
The experiment, part of a...
By Carissa Wong, New Scientist | 07.01.2022
Photo by CDC on Unsplash
A new form of the genome-editing technique CRISPR could provide a more accurate way to edit mutations that cause genetic diseases. The approach, which was tested in fruit flies, fixes a genetic mutation on one...